{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:00:11Z","timestamp":1793638811037,"version":"4.5.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T00:00:00Z","timestamp":1563753600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T00:00:00Z","timestamp":1563753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100015979","name":"Pelotonia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015979","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013650","name":"Morphosys","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013650","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010878","name":"AbbVie Biotherapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010878","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007136","name":"Karyopharm Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007136","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100014491","name":"Pharmacyclics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014491","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Janssen"},{"name":"Acerta"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015234","name":"Sunesis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015234","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Innate Pharma"},{"name":"Genetech"},{"name":"Gilead"},{"name":"Acerta Pharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s00520-019-04991-y","type":"journal-article","created":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T08:03:56Z","timestamp":1563782636000},"page":"1799-1807","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Identifying risk factors for depression and anxiety symptoms in patients with chronic lymphocytic leukemia"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1074-7787","authenticated-orcid":false,"given":"Abigail S.","family":"Robbertz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrukh T.","family":"Awan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry A.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,22]]},"reference":[{"issue":"2\u20133","key":"4991_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jad.2012.03.025","volume":"141","author":"W Linden","year":"2012","unstructured":"Linden W, Vodermaier A, MacKenzie R, Greig D (2012) Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. J Affect Disord 141(2\u20133):343\u2013351. \nhttps:\/\/doi.org\/10.1016\/j.jad.2012.03.025","journal-title":"J Affect Disord"},{"key":"4991_CR2","unstructured":"Commision on Cancer of the American College of Surgeons. (2016). Cancer Program Standards: Ensuring Patient-Centered Care, 8\u201315, 73"},{"key":"4991_CR3","unstructured":"Howell D, Keshavarz H, Esplen MJ, Hack T, Hamel M, Howes J, Jones J, Li M, Manii D, McLeod D, Meyer C, Sellick S, Riahizadeh S, Noroozi H A. M. (2015). A Pan Canadian Practice Guideline: screening, assessment and care of psychosocial distress (Depression, Anxiety) in adults with cancer: Canadian Partnership Against Cancer (Cancer Journey Advisory Group) and Canadian Association of Psychosocial Oncology. Toronto: Canadian Partnership Against Cancer and the Canadian Association of Psychosocial Oncology"},{"issue":"15","key":"4991_CR4","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1200\/JCO.2013.52.4611","volume":"32","author":"B Andersen","year":"2014","unstructured":"Andersen B, DeRubeis R, Berman B, Gruman J, Champion V, Massie MJ et al (2014) Screening, assessment, and care of anxiety and depression symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. J Clin Oncol 32(15):1605\u20131619. \nhttps:\/\/doi.org\/10.1200\/JCO.2013.52.4611","journal-title":"J Clin Oncol"},{"key":"4991_CR5","unstructured":"Patient and Survivor Care. (2014). American Society of Clinical Oncology. Retrieved from \nhttps:\/\/www.asco.org\/practice-guidelines\/quality-guidelines\/guidelines\/patient-and-survivor-care#\/9656"},{"issue":"5","key":"4991_CR6","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1440-1614.2004.01358.x","volume":"38","author":"DW Kissane","year":"2004","unstructured":"Kissane DW, Grabsch B, Love A, Clarke DM, Blosch S, Smith GC (2004) Psychiatric disorder in women with early stage and advanced breast cancer: a comparative analysis. Aust N Z J Psychiatry 38(5):320\u2013326. \nhttps:\/\/doi.org\/10.1111\/j.1440-1614.2004.01358.x","journal-title":"Aust N Z J Psychiatry"},{"issue":"8","key":"4991_CR7","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1007\/s00520-014-2571-y","volume":"23","author":"L Stafford","year":"2015","unstructured":"Stafford L, Judd F, Gibson P, Komiti A, Mann GB, Quinn M (2015) Anxiety and depression symptoms in the 2 years following diagnosis of breast or gynaecologic cancer: prevalence, course and determinants of outcome. Support Care Cancer 23(8):2215\u20132224. \nhttps:\/\/doi.org\/10.1007\/s00520-014-2571-y","journal-title":"Support Care Cancer"},{"issue":"6","key":"4991_CR8","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/nbt.3121.ChIP-nexus","volume":"24","author":"T Weiss Wiesel","year":"2015","unstructured":"Weiss Wiesel T, Nelson C, Tew W, Hardt M, Mohile S, Owusu C et al (2015) The relationship between age, anxiety, and depression in older adults with cancer. Psychooncology 24(6):712\u2013717. \nhttps:\/\/doi.org\/10.1038\/nbt.3121.ChIP-nexus","journal-title":"Psychooncology"},{"issue":"3","key":"4991_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0149421","volume":"11","author":"MP Lima","year":"2016","unstructured":"Lima MP, Longatto-Filho A, Os\u00f3rio FL (2016) Predictor variables and screening protocol for depression and anxiety disorders in cancer outpatients. PLoS One 11(3):1\u201313. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0149421","journal-title":"PLoS One"},{"issue":"10","key":"4991_CR10","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1007\/s00520-013-1854-z","volume":"21","author":"CL Pashos","year":"2013","unstructured":"Pashos CL, Flowers CR, Kay NE, Weiss M, Lamanna N, Farber C, Lerner S, Sharman J, Grinblatt D, Flinn IW, Kozloff M, Swern AS, Street TK, Sullivan KA, Harding G, Khan ZM (2013) Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia. Support Care Cancer 21(10):2853\u20132860. \nhttps:\/\/doi.org\/10.1007\/s00520-013-1854-z","journal-title":"Support Care Cancer"},{"issue":"12","key":"4991_CR11","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1002\/pon.4893","volume":"27","author":"RL Rohde","year":"2018","unstructured":"Rohde RL, Adjei Boakye E, Challapalli SD, Patel SH, Geneus CJ, Tobo BB, Simpson MC, Mohammed KA, Deshields T, Varvares MA, Osazuwa-Peters N (2018) Prevalence and sociodemographic factors associated with depression among hospitalized patients with head and neck cancer\u2014results from a national study. Psycho-Oncology 27(12):2809\u20132814. \nhttps:\/\/doi.org\/10.1002\/pon.4893","journal-title":"Psycho-Oncology"},{"issue":"3","key":"4991_CR12","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00277-017-3198-0","volume":"97","author":"AJ Shreders","year":"2018","unstructured":"Shreders AJ, Niazi SK, Hodge DO, Chimato NT, Kureti M, Kirla N, Agrawal A, Swaika A, Gustetic E, Foster R, Nelson KA, Jani P, Chanan-Khan AA, Ailawadhi S (2018) Correlation of sociodemographic and clinical parameters with depression and distress in patients with hematologic malignancies. Ann Hematol 97(3):519\u2013528. \nhttps:\/\/doi.org\/10.1007\/s00277-017-3198-0","journal-title":"Ann Hematol"},{"key":"4991_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4046\/trd.2018.0048","volume":"81","author":"KK Shahedah","year":"2018","unstructured":"Shahedah KK, How SH, Jamalludin AR, Mohd Faiz MT, Kuan YC, Ong CK (2018) Depression symptoms in newly diagnosed lung carcinoma: prevalence and associated risk factors. Tuberc Respir Dis 81:1\u201310. \nhttps:\/\/doi.org\/10.4046\/trd.2018.0048","journal-title":"Tuberc Respir Dis"},{"issue":"8","key":"4991_CR14","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1002\/cncr.22980","volume":"110","author":"M Miovic","year":"2007","unstructured":"Miovic M, Block S (2007) Psychiatric disorders in advanced cancer. Cancer 110(8):1665\u20131676. \nhttps:\/\/doi.org\/10.1002\/cncr.22980","journal-title":"Cancer"},{"issue":"4","key":"4991_CR15","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.ejca.2007.12.013","volume":"44","author":"AE Simon","year":"2008","unstructured":"Simon AE, Wardle J (2008) Socioeconomic disparities in psychosocial wellbeing in cancer patients. Eur J Cancer 44(4):572\u2013578. \nhttps:\/\/doi.org\/10.1016\/j.ejca.2007.12.013","journal-title":"Eur J Cancer"},{"issue":"11","key":"4991_CR16","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1002\/pon.3309","volume":"22","author":"MA Andrykowski","year":"2013","unstructured":"Andrykowski MA, Aarts MJ, Van De Poll-Franse LV, Mols F, Slooter GD, Thong MSY (2013) Low socioeconomic status and mental health outcomes in colorectal cancer survivors: disadvantage? advantage?\u22ef or both? Psycho-Oncology 22(11):2462\u20132469. \nhttps:\/\/doi.org\/10.1002\/pon.3309","journal-title":"Psycho-Oncology"},{"issue":"4","key":"4991_CR17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1176\/appi.psy.50.4.383","volume":"50","author":"TT Levin","year":"2009","unstructured":"Levin TT, Brintzenhofe-Szoc KM, Kissane DW, Zabora JR, Li Y (2009) Mixed anxiety\/depression symptoms in a large cancer cohort: prevalence by cancer type. Psychosomatics 50(4):383\u2013391. \nhttps:\/\/doi.org\/10.1176\/appi.psy.50.4.383","journal-title":"Psychosomatics"},{"issue":"2","key":"4991_CR18","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S1470-2045(11)70002-X","volume":"12","author":"AJ Mitchell","year":"2011","unstructured":"Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, Meader N (2011) Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. The Lancet Oncology 12(2):160\u2013174. \nhttps:\/\/doi.org\/10.1016\/S1470-2045(11)70002-X","journal-title":"The Lancet Oncology"},{"issue":"4","key":"4991_CR19","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/pon.4153","volume":"26","author":"L Zhu","year":"2017","unstructured":"Zhu L, Ranchor AV, van der Lee M, Garssen B, Almansa J, Sanderman R, Schroevers MJ (2017) Co-morbidity of depression, anxiety and fatigue in cancer patients receiving psychological care. Psycho-Oncology 26(4):444\u2013451. \nhttps:\/\/doi.org\/10.1002\/pon.4153","journal-title":"Psycho-Oncology"},{"issue":"9","key":"4991_CR20","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s00520-009-0577-7","volume":"17","author":"WY Cheung","year":"2009","unstructured":"Cheung WY, Le LW, Zimmermann C (2009) Symptom clusters in patients with advanced cancers. Support Care Cancer 17(9):1223\u20131230. \nhttps:\/\/doi.org\/10.1007\/s00520-009-0577-7","journal-title":"Support Care Cancer"},{"key":"4991_CR21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1080\/0284186X.2016.1266090","volume":"56","author":"R Caruso","year":"2017","unstructured":"Caruso R, Nanni MG, Riba M, Sabato S, Mitchell AJ, Croce E, Grassi L (2017) Depression spectrum disorders in cancer: prevalence, risk factors and screening for depression: a critical review. Acta Oncol 56:146\u2013155. \nhttps:\/\/doi.org\/10.1080\/0284186X.2016.1266090","journal-title":"Acta Oncol"},{"key":"4991_CR22","doi-asserted-by":"publisher","unstructured":"Henry M, Fuehrmann F, Hier M, Zeitouni A, Kost K, Richardson K, Mlynarek A, Black M, MacDonald C, Chartier G, Zhang X, Rosberger Z, Frenkiel S (2019) Contextual and historical factors for increased levels of anxiety and depression in patients with head and neck cancer: a prospective longitudinal study. Head Neck 2(February). \nhttps:\/\/doi.org\/10.1002\/hed.25725","DOI":"10.1002\/hed.25725"},{"issue":"8","key":"4991_CR23","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1191\/0269216304pm950oa","volume":"18","author":"H-K Chang","year":"2004","unstructured":"Chang H-K, Chen M-L (2004) Physical symptom profiles of depressed and nondepressed patients with cancer. Palliat Med 18(8):712\u2013718. \nhttps:\/\/doi.org\/10.1191\/0269216304pm950oa","journal-title":"Palliat Med"},{"issue":"Cll","key":"4991_CR24","doi-asserted-by":"publisher","first-page":"17008","DOI":"10.1038\/nrdp.2017.8","volume":"3","author":"TJ Kipps","year":"2017","unstructured":"Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG et al (2017) Chronic lymphocytic leukaemia. Nat Rev Dis Prim 3(Cll):17008. \nhttps:\/\/doi.org\/10.1038\/nrdp.2017.8","journal-title":"Nat Rev Dis Prim"},{"issue":"9","key":"4991_CR25","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/ajh.24826","volume":"92","author":"M Hallek","year":"2017","unstructured":"Hallek M (2017) Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol 92(9):946\u2013965. \nhttps:\/\/doi.org\/10.1002\/ajh.24826","journal-title":"Am J Hematol"},{"issue":"9","key":"4991_CR26","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/cncr.31931","volume":"125","author":"Sandhya Sharma","year":"2019","unstructured":"Sharma, S., & Rai, K. R. (2019). Chronic lymphocytic leukemia (CLL) treatment: so many choices, such great options. Cancer, (Cll), 1\u20139. doi:\nhttps:\/\/doi.org\/10.1002\/cncr.31931","journal-title":"Cancer"},{"issue":"1","key":"4991_CR27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.cger.2015.08.006","volume":"32","author":"S Wall","year":"2016","unstructured":"Wall S, Woyach JA (2016) Chronic lymphocytic leukemia and other lymphoproliferative disorders. Clin Geriatr Med 32(1):175\u2013189. \nhttps:\/\/doi.org\/10.1016\/j.cger.2015.08.006","journal-title":"Clin Geriatr Med"},{"issue":"15_suppl","key":"4991_CR28","doi-asserted-by":"publisher","first-page":"7007","DOI":"10.1200\/jco.2014.32.15_suppl.7007","volume":"32","author":"JP Sharman","year":"2019","unstructured":"Sharman JP, Klein LM, Boxer M, Kolibaba KS, Abella-Dominicis E, Hawkins MJ et al (2019) Phase 2 trial of GS-9973, a selective Syk inhibitor, in chronic lymphocytic leukemia (CLL). J Clin Oncol 32(15_suppl):7007\u20137007. \nhttps:\/\/doi.org\/10.1200\/jco.2014.32.15_suppl.7007","journal-title":"J Clin Oncol"},{"issue":"15","key":"4991_CR29","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1002\/cncr.31538","volume":"124","author":"BL Andersen","year":"2018","unstructured":"Andersen BL, Goyal NG, Weiss DM, Westbrook TD, Maddocks KJ, Byrd JC, Johnson AJ (2018) Cells, cytokines, chemokines, and cancer stress: a biobehavioral study of patients with chronic lymphocytic leukemia. Cancer 124(15):3240\u20133248. \nhttps:\/\/doi.org\/10.1002\/cncr.31538","journal-title":"Cancer"},{"issue":"2","key":"4991_CR30","doi-asserted-by":"publisher","first-page":"e0192097","DOI":"10.1371\/journal.pone.0192097","volume":"13","author":"Claire Kim","year":"2018","unstructured":"Kim, C., Wright, F. C., Look Hong, N. J., Groot, G., Helyer, L., Meiers, P., Quan M. L., Urquhart R., Warburton R. Gagliardi, A. R. (2018). Patient and provider experiences with active surveillance: a scoping review. PLoS One, 13(2), 1\u201317. doi:\nhttps:\/\/doi.org\/10.1371\/journal.pone.0192097","journal-title":"PLOS ONE"},{"issue":"3","key":"4991_CR31","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.genhosppsych.2007.01.014","volume":"29","author":"TT Levin","year":"2007","unstructured":"Levin TT, Li Y, Riskind J, Rai K (2007) Depression, anxiety and quality of life in a chronic lymphocytic leukemia cohort. Gen Hosp Psychiatry 29(3):251\u2013256. \nhttps:\/\/doi.org\/10.1016\/j.genhosppsych.2007.01.014","journal-title":"Gen Hosp Psychiatry"},{"issue":"2","key":"4991_CR32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1365-2141.2007.06791.x","volume":"139","author":"TD Shanafelt","year":"2007","unstructured":"Shanafelt TD, Bowen D, Venkat C, Slager SL, Zent CS, Kay NE, Reinalda M, Sloan JA, Call TG (2007) Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. Br J Haematol 139(2):255\u2013264. \nhttps:\/\/doi.org\/10.1111\/j.1365-2141.2007.06791.x","journal-title":"Br J Haematol"},{"key":"4991_CR33","unstructured":"Acalabruntinib in Combination With Obinutuzumab in Relapsed\/Refractory or Untreated CLL\/SLL\/PLL. (2016). \nclincialtrials.gov\n\n\n. Retrieved from \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02296918?term=02296918&rank=1"},{"key":"4991_CR34","unstructured":"Bcl-2 inhibitor GDC-0199 in combination with obinutuzumab and ibrutinib in treating patients with relapsed, refractory, or previously untreated chronic lymphocytic leukemia. (2017). \nclincialtrials.gov\n\n\n. Retrieved from \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02427451?term=OSU+14266&cond=CLL&cntry1=NA%3AUS&state1=NA%3AUS%3AOH&rank=1"},{"key":"4991_CR35","unstructured":"Pharmacyclic LLC. (n.d.). Ibrutinib as an immune modulating agent for patients with asymptomatic, high-risk CLL\/SLL risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Retrieved April 8, 2019, from \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02518555?term=OSU+15012&cond=Chronic+Lymphocytic+Leukemia&cntry1=NA%3AUS&state1=NA%3AUS%3AOH&rank=1"},{"key":"4991_CR36","doi-asserted-by":"crossref","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie R (1987) A new method of classifying prognostic in longitudinal studies: development and validation. J Chronic Dis:0021\u20139681\/87","DOI":"10.1016\/0021-9681(87)90171-8"},{"issue":"158","key":"4991_CR37","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1001\/jama.2016.8474","volume":"41","author":"L Horowitz","year":"1979","unstructured":"Horowitz L, Wilner M, Alvarez N, Weiss W, Marmar DS, Neal CR et al (1979) Revised impact of event scale (22 questions). Psychosomatic Medicine. J Trauma Stress J Trauma Stress J Nerv Mental Dis Behav Res Ther Am J Psychiatry 41(158):209\u2013218. \nhttps:\/\/doi.org\/10.1001\/jama.2016.8474","journal-title":"J Trauma Stress J Trauma Stress J Nerv Mental Dis Behav Res Ther Am J Psychiatry"},{"issue":"2","key":"4991_CR38","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/oxfordjournals.aje.a112674","volume":"109","author":"LF Berkman","year":"1979","unstructured":"Berkman LF (1979) Social networks, host-resistance, and mortality--9 year follow-up study of Alameda County residents. Am J Epidemiol 109(2):186\u2013204","journal-title":"Am J Epidemiol"},{"issue":"1","key":"4991_CR39","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cellimm.2011.04.003","volume":"270","author":"BL Mundy-Bosse","year":"2011","unstructured":"Mundy-Bosse BL, Thornton LM, Yang H-C, Andersen BL, Carson WE (2011) Psychological stress is associated with altered levels of myeloid-derived suppressor cells in breast cancer patients. Cell Immunol 270(1):80\u201387. \nhttps:\/\/doi.org\/10.1016\/j.cellimm.2011.04.003","journal-title":"Cell Immunol"},{"issue":"32","key":"4991_CR40","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/jncimonographs\/lgh010","volume":"2004","author":"PB Jacobsen","year":"2004","unstructured":"Jacobsen PB (2004) Assessment of fatigue in cancer patients. J Natl Cancer Inst Monogr 2004(32):93\u201397. \nhttps:\/\/doi.org\/10.1093\/jncimonographs\/lgh010","journal-title":"J Natl Cancer Inst Monogr"},{"key":"4991_CR41","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JBW (2001) The PHQ-9. J Gen Intern Med 16:606\u2013613. \nhttps:\/\/doi.org\/10.1046\/j.1525-1497.2001.016009606.x","journal-title":"J Gen Intern Med"},{"issue":"10","key":"4991_CR42","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","volume":"166","author":"RL Spitzer","year":"2006","unstructured":"Spitzer RL, Kroenke K, Williams JBW, L\u00f6we B (2006) A brief measure for assessing generalized anxiety disorder. Arch Intern Med 166(10):1092\u20131097. \nhttps:\/\/doi.org\/10.1001\/archinte.166.10.1092","journal-title":"Arch Intern Med"},{"issue":"4","key":"4991_CR43","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/abm\/kax004","volume":"52","author":"NG Goyal","year":"2018","unstructured":"Goyal NG, Maddocks KJ, Johnson AJ, Byrd JC, Westbrook TD, Andersen BL (2018) Cancer-specific stress and trajectories of psychological and physical functioning in patients with relapsed\/refractory chronic lymphocytic leukemia. Ann Behav Med 52(4):287\u2013298","journal-title":"Ann Behav Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-04991-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-019-04991-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-04991-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T23:25:09Z","timestamp":1595287509000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-019-04991-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,22]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["4991"],"URL":"https:\/\/doi.org\/10.1007\/s00520-019-04991-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,22]]},"assertion":[{"value":"17 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Abigail S. Robbertz has no COI. Dave M. Weiss received funding from Pelatonia. Dr. Farrukh T. Awan received funding from AbbVie, Pharmacyclics, Janssen, AstraZeneca, Sunesis, Innate Pharma, Genetech, and Gilead. Dr. John C. Byrd has no COI. Dr. Kerry A. Rogers received funding from Genetech and Acerta. Dr. Jennifer A. Woyach received funding from Morphosys, AbbVie, Karyopharm, Pharmacyclics, Janssen, and Acerta.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}